Origin Sciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Origin Sciences is pioneering a new approach to gastrointestinal diagnostics centered on the analysis of rectal mucus, a previously underutilized biospecimen. The company's core technology is the OriCol device, a simple, proprietary medical device for collecting high-quality rectal mucosal samples, enabling the detection of biomarkers for conditions like colorectal cancer and adenomatous polyps. By combining this novel sampling method with advanced genomic analysis in its own laboratory, Origin aims to deliver more accurate, cost-effective, and patient-friendly diagnostic pathways. The company is actively engaged in clinical studies and partnerships, such as with Primerdesign, to validate and commercialize its extraction and analysis workflow.

GastrointestinalOncologyGynecological

Technology Platform

Proprietary medical device (OriCol) for non-invasive collection of rectal mucosal samples, combined with an in-house genomics laboratory utilizing hologenomic (host-microbe) sequencing and bioinformatics for biomarker discovery and diagnostic assay development.

Opportunities

The primary opportunity lies in disrupting the large and growing colorectal cancer screening market with a more accurate, patient-friendly, and cost-effective test based on a novel biospecimen.

The platform's broad applicability to other GI and gynecological diseases offers significant market expansion potential.

Strategic partnerships can accelerate regulatory pathways and commercial distribution.

Risk Factors

Key risks include the failure of larger clinical trials to validate diagnostic accuracy, challenges in obtaining regulatory approval for a novel device and biospecimen, and difficulties in achieving market adoption and reimbursement against established competitors.

As a small, private company, execution risk and funding needs are also significant.

Competitive Landscape

Origin competes in the non-invasive CRC screening space against large players like Exact Sciences (Cologuard) and Guardant Health (Shield), as well as standard FIT tests. Its differentiation is the novel rectal mucus biospecimen and hologenomic analysis approach. It also faces competition from other early-stage companies developing next-generation liquid and microbiome-based biopsies for GI health.

More companies in United Kingdom →